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Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes
is a series of Editorials which is published on a biannual basis by the Editorial Board of the Medicinal
Chemistry section of the journal Molecules. In these Editorials, we highlight in brief reports (of about
one hundred words) a number of recently published articles that describe crucial findings, such as the
discovery of novel drug targets and mechanisms of action or novel classes of drugs, which may inspire
future medicinal chemistry endeavors devoted to addressing prime unmet medical needs.
2. Inhibition of 5-Lipoxygenase-Activating Protein: A New Therapeutic Strategy to Combat
Residual Inflammatory Risk in Patients with Ischaemic Heart Disease?
Highlighted by Arduino A. Mangoni
A significant number of patients suffer from coronary events despite being on maximal treatment
with cardioprotective drugs. This suggests the presence of residual cardiovascular risk. Recent evidence
highlights the key role of specific pro-inflammatory pathways in driving this residual risk and the need
for novel, more effective treatments [1]. Pettersen et al. report the discovery and optimization of a
series of novel inhibitors of 5-lipooxygenase-activating protein, which stimulates the production of
leukotrienes, important mediators in the pathogenesis and progression of atherosclerosis [2]. In particular,
compound AZD5718, (1R,2R)-2-{4-[3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]benzoyl}-
N-(4-oxo-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide, demonstrated a
favorable pharmacokinetic and safety profile in rats and dogs [3]. This led to phase-I studies in
healthy subjects, which showed a strong relationship between plasma concentrations of AZD5718 and
inhibition of both leukotriene B4, involved in inflammation, and leukotriene E4, a cysteinyl leukotriene
also involved in inflammation [3]. Pending further investigations in patients with ischaemic heart
disease, the results of this study suggest that inhibition of 5-lipooxygenase-activating protein might
represent a promising therapeutic strategy to target residual inflammatory cardiovascular risk in
specific patient populations.
3. Repurposing Ticagrelor: When an Antiplatelet Drug Could Emerge as a Potent
Antibacterial Agent
Highlighted by Jean Jacques Vanden Eynde
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Ticagrelor (A; CAS 274693-27-5) is a trisubstituted triazolo[4,5-d]pyrimidine acting as a
blood-thinning agent by reversibly inhibiting the interactions between ADP and the P2Y12 protein
(Figure 1). By preventing platelets aggregation, it reduces the risk of cardiovascular events in patients
with acute coronary syndromes. The drug was approved in European Union at the end of 2010 and by
the Food and Drug Administration in the middle of 2011. Recently, it was reported [4] that the drug
could improve lung function in patients suffering from pneumonia. Inspired by those observations, P.
Lancellotti et al. [5] screened ticagrelor and some of its metabolites for their activity, in vitro and in vivo
(mouse models), against several strains of Gram-positive and Gram-negative bacteria. Interestingly,
ticagrelor and one metabolite exhibited a bactericidal activity superior to that of vancomycin against
selected antibiotic-resistant Gram-positive bacteria.
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4. Anticancer Effective Tantalum Organo-Complexes
Highlighted by Josef Jampilek
Despite the approval of many anti-proliferative/anticancer drugs, cancer remains the second
leading cause of death worldwide. Platinum-based alkylating antitumor chemotherapeutics, of
which cisplatin is the best known, exhibit any adverse effects and, in addition, are associated
ith frequent tumor cell resistance. To innovate this class of drugs, a wide range of metal-based
complexes with ruthenium, rhodium, osmium, iridium, molybdenum, iron, gold, and copper has
been designed [6]. Recently, unique new electroneutral half-sandwich tantalum(V) dichlorido
complexes containing pentamethylcyclopentadienyl (Cp*) and the double-deprotonated version
of the Schiff base 2-{(E)-[(2-hydroxyphenyl)imino]methyl}phenol or 2-ethoxy-6-{(E)-[(2-hydroxy-
phenyl)imino]methyl}phenol as ligands were reported as potential anticancer agents. In general, both
tantalum organo-complexes [Ta(η5-Cp*)(L)Cl2] showed better cytotoxic potency in cisplatin-resistant
cell lines (A2780R and HOS) as well as cisplatin-sensitive A2780 cells than cisplatin [7,8]. In addition,
it is extremely important that they demonstrated markedly lower toxicity in non-tumor MRC-5 cells
(IC50 > 50 µM) and in primary human hepatocytes (IC50 > 100 µM) than cisplatin and oxaliplatin [7–9].
Thus, these tantalum(V)-based complexes seem to be promising new anticancer agents.
5. Design, Synthesis, and Biological Activities of New Pyrazole Derivatives Possessing Both
Coxib and Combretastatins Pharmacophores
Highlighted by Dimitra Hadjipavlou-Litina
In the past decade, studies have reported a growing body of data on different pyrazole derivatives
and their innumerable physiological and diverse pharmacological activities.
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Molecular hybridization is an approach in rational drug design where new chemical entities are
obtained by combining two or more pharmacophoric moieties into a single molecule [10]. It is believed
that the hybrid will present better bioactivity and pharmacokinetic profile than the original molecules.
Combretastatin A-4 is a tubulin-binding chemotherapy drug that is structurally related to colchicine.
Thi et al. [11] tried to discover novel multi-target agents with better anti-tumor activities than celecoxib.
Twenty-one new aryl-substituted pyrazole derivatives possessing a cis-diphenylethylene scaffold were
mostly synthesized by a one-pot approach to ethyl 1,4,5-triaryl-1H-pyrazole-3-carboxylates via an
improved Claisen condensation–Knorr reaction sequence. The hybrids were tested against the three
human cancer cell lines HT-29, Hep-G2, and MCF-7. The inhibition of NO production was studied.
The results showed that incorporation of the two important pharmacophoric groups of the two original
molecules celecoxib and combretastatin A-4 in a single hybrid molecule leads to better biological
activities of the new coxib-hybrided compounds.
6. Novel Epoxyketone-Based Proteasome Inhibitors with Enhanced Metabolic Stability and
Activity against PI-Resistant Models
Highlighted by Hong Liu
Proteasome inhibitors (PIs) have significantly improved the overall survival and quality of life of
multiple myeloma (MM) patients. However, cancer resistance, either de novo or acquired, remains a
major obstacle in expanding the clinical utility of PI drugs. Kyung Bo Kim and his co-workers have
developed a series of peptide epoxyketones bearing a P1′-targeting moiety, of which the most potent
Cfz−OH (IC50 = 29.4 nM) showed an IC50 value against H23 cells similar to that of carfilzomib (Cfz,
IC50 = 18.3 nM) [12]. Moreover, Cfz−OH demonstrated improved potency by ~10-fold and 3-fold
relative to Cfz in models of de novo and acquired Cfz resistance, respectively. On the other hand,
the addition of a hydroxyl group adjacent to the epoxide ring of Cfz hindered the hydrolysis of the
epoxide ring by inhibiting access to the active site of mEH. This work may provide us with a new
direction for the development of new-generation PIs with enhanced metabolic stability and activity
against PI-resistant patients.
7. Tyrosyl-DNA Phosphodiesterase 1 as a Novel Target to Enhance the Efficacy and Utility of
Topotecan and Irinotecan
Highlighted by Jóhannes Reynisson
Many of the anticancer drugs used in the clinic are based on targeting the rapidly dividing
malignant cells. These include DNA-damaging agents, which push the cancer cells into, e.g., apoptosis
or necrosis. Topotecan and irinotecan are well-established topoisomerase 1 (Top1) poisons used against
many cancer types. It has been shown that Tyrosyl-DNA phosphodiesterase 1 (TDP1) counteracts the
effect of these drugs by unravelling the stalled DNA-Top1 complex, allowing cancer cells to survive
the chemotherapeutic regime. Now reports have emerged of potent and selective small molecular
inhibitors of TDP1 [13], which have the potential to dramatically increase the efficacy of topotecan
and irinotecan as well as extend their application to other cancer types such as triple-negative breast
cancer. In particular, it has been found that the adjunctive administration of TDP1 inhibitor with
topotecan substantially reduces metastasis growth in Lewis lung carcinoma models, making TDP1 a
very promising therapeutic target [13].
8. “KISS” Antimicrobial Peptides: “Keep It Simple and Stable” to Reach Selective
New Antibiotics
Highlighted by Maria Emília Sousa
One breakthrough in the field of antibiotics has been the discovery of new antimicrobial peptides
(AMPs). Membrane-active AMPs are appealing due to their low propensity for inducing the
development of resistance but still present drawbacks such as toxicity, susceptibility to proteases, and
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manufacturing costs. Inspired by Svendsen and co-workers [14], who defined the pharmacophore of
AMPs as two cationic charges and two bulky hydrophobic aromatic units, Boullet et al. [15], with the
idea of keeping the AMPs simple and stable, synthetized newβ2,2- andβ3,3-bis-homo-ornithine/arginine
peptides. This series of cationic peptides combined with the supertryptophan residue furnished AMPs
with MIC values in the range of 2 to 16 µg/mL, active against both Gram-positive and Gram-negative
bacteria. Structure-activity relationship studies were stablished, and a hit dipeptide emerged. This
β2,2-amino acid derivative, easier to synthesize, showed to destabilize the bacterial membrane, revealed
low hemolytic and cytolytic activities in mammalian cells, and was stable in human serum. The in vivo
results highlight the potential of this new AMP for the treatment of sepsis in mice and the success of
simple ideas for complex problems.
9. Amino Acid-Based Prodrugs of a Fosmidomycin Surrogate as Antimalarial and
Antitubercular Agents
Highlighted by Paula A. C. Gomes
Malaria, tuberculosis (TB), and AIDS form the so-called “Big Three” triad of the most worrisome
infectious diseases of the world. This terrible triad imposes a heavy toll especially to people from low-
and middle-income countries (LMIC), where treatment options that are affordable to patients remain
scarce. This is further aggravated when the etiological agents of the “Big Three” simultaneously affect
the same person, causing AIDS/TB, malaria/AIDS, or malaria/TB co-infections, with quite discouraging
prognoses. Medicinal chemistry efforts to find new low-cost strategies against the “Big Three” are not
merely significant, but unquestionably urgent. A new opportunity towards this end was now opened
upon the disclosure of fosmidomycin-inspired prodrugs as antimalarial and antitubercular leads, by
Courtens et al. [16]. Fosmidomycin is a natural antibiotic whose antimalarial potential was unveiled
at the turn of the 20th to the 21st century [17], paving the way towards the use of fosmidomycin in
antimalarial combination therapies [18]. The recent work by Courtens et al. contributes to expand
the chemical space around fosmidomycin and brings hope for future candidate drugs to tackle
malaria/TB co-infections.
10. Horizon for a Prenatal Prevention of Cystic Fibrosis?
Highlighted by Katalin Prokai-Tatrai
Cystic fibrosis (CF) is a devastating genetic disease caused by mutations in the CF transmembrane
conductance regulator (CFTR) gene that encodes the anion channel CFTR protein. The hallmark of CF
is the accumulation of thick, sticky mucus that can damage multiple organs in the body, ultimately
leading to diminished quality of life and early death. With the use of small-molecule CFTR potentiators,
it may be possible to correct the defective CFTR channel in patients with specific CFTR mutations.
Ivacaftor [N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide] is such a
potentiator that can be given orally to patients as young as two years old. As symptoms of the disease
may start before birth, Sun et al. [19] have used a ferret model of CF with specific mutations to pre- and
postnatally administer ivacaftor. The authors found that prenatal administration to pregnant ferrets
protected the fetuses against in utero development of CFTR defects and partially protected against the
development of CF-related organ pathologies. At the same time, the authors also showed that postnatal
ivacaftor withdrawal restored CFTR pathologies. These findings raise the hope that the prevention
of CF-related pathologies may be possible before or soon after birth with timely administration of
targeted therapies.
11. Small-Molecule PROTACs: A Promising Approach for the Development of Selective Drugs
Highlighted by Tiziano Tuccinardi
The PROteolysis-TArgeting Chimera (PROTAC) technology has emerged as a promising
therapeutic tool that induces protein degradation by exploiting the ubiquitin proteasome system.
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This approach takes advantage of a two-headed molecule including a small molecule binder of a
target protein (termed warhead), an E3 ligase-recruiting moiety, and a linker which connects these
two portions of the molecule. By using the same warhead and the same recruited E3 ligase while
modifying only the linker length and its attaching point on the E3 ligase-recruiting moiety, Crews and
co-workers were able to identify two PROTACs that targeted individual isoforms of the p38 MAPK
family [20]. Their results open a new way to develop selective drugs and highlight that the formation
of the ternary complex (target protein–PROTAC–E3 ubiquitin ligase) is necessary but not sufficient for
the PROTAC-induced substrate ubiquitination.
12. Screen Using Huge Virtual Docking Library to Accelerate the Discovery of Candidate Drugs
Highlighted by Jean-Marc Sabatier
In order to accelerate the discovery of candidate drugs, Lyu and collaborators [21] examined
the virtual docking of 170 million molecules (from 130 known chemical reactions) against AmpC
β-lactamase (AmpC) and the D4 dopamine receptor. According to this computer-based virtual
screening, the authors selected 44 (for AmpC) and 549 (for the D4 dopamine receptor) candidate
ligands/drugs which were chemically produced and experimentally tested for binding to their molecular
targets. Interestingly, this approach allowed, in both cases, to discover the best-in-class molecules,
including a novel family of highly potent (non-covalent) phenolate-based AmpC inhibitors. From the
data, it therefore appears that bigger, ultra-large docking libraries are actually appropriate for the rapid
and efficient discovery of new candidate drugs in the various areas of biomedical research.
13. Expanding the Range of Targeted Residues for the Design of Covalent Inhibitors
Highlighted by F. Javier Luque
The incorporation of a reactive “warhead” into a reversible recognition element underlies the
design of chemical probes and drug candidates able to covalently bind to a target protein. Targeted
covalent inhibitors (TCIs) combine improved potency and prolonged duration of action, but these
advantages may be compromised by overly reactivity, which in turn may affect target selectivity. With
the aim to expand the range of applicability of TCIs, Liu and coworkers have explored the possibility
of designing lysine-target covalent inhibitors. In their work, they resorted to the usage of constant-pH
molecular dynamics simulations to identify reactive catalytic lysines in a series of human kinases.
These calculations disclosed the presence of reactive catalytic lysines (pKa < 7.8), suggesting that they
may occur in a rarely populated conformational state. Overall, this computational strategy gives rise to
the design of suitably modified type II inhibitors to expand the arsenal tool of selective drugs targeting
the human kinome [22].
14. Amino Acid Versus Phosphate Ester Prodrugs for Improving the Oral Bioavailability
of Atazanavir
Highlighted by Jarkko Rautio
Atazanavir is an HIV-1 protease inhibitor suffering from suboptimal physicochemical properties
that contribute to its poor absorption and susceptibility to both efflux and CYP-mediated metabolism.
Both amino acid and phosphate ester prodrugs were produced to address these limitations. Although
the direct phosphorylation of the secondary alcohol moiety resulted in the chemically stable
phosphate monoester with significantly improved solubility, the prodrug failed to improve the
oral absorption of atazanavir in rats due to inefficient bioconversion to the parent drug in the intestine.
The phosphonooxymethyl prodrug with comparable solubility was more susceptible to intestinal
bioconversion and provided a reasonable systemic exposure to atazanavir. Screening various amino acid
prodrugs to overcome the barriers of both efflux and metabolism in addition to solubility-related issues
resulted in the discovery of the L–Phe–Sar dipeptide prodrug that takes advantage of a self-immolative
process of drug release. The prodrug provided a four-fold improved AUC and an eight-fold improved
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C24h value compared with an equivalent dose of the parent drug itself. This prodrug design appears to
offer a viable strategy for addressing solubility issues of sterically hindered alcohols [23].
15. A General Method to Quantify Ligand-Driven Oligomerization from
Fluorescence-Based Images
Highlighted by Rafik Karaman
To produce a therapeutic effect, a drug must first bind to specific receptors in the cell membranes.
Receptors tend to change their molecular structure in a variety of ways during binding; only the
right structure will “unlock” the drug’s therapeutic effect. Recently, a new method was developed by
two research teams, using fluorescence-based images for assessing the therapeutic effects of drugs
by matching them to their unique receptors [24]. This method has a great potential to enhance drug
development and reduce the number of failing drug trials.
The method monitors the oligomerization process that occurs when a receptor generally exists as
a single subunit but shifts to a multi-structure (an oligomer) in the presence of the drug, or vice versa.
The method was tested using fused fluorescent proteins and was validated on a receptor for the
epidermal growth factor (EGF), whose malfunction is often linked to cancer. The activation of the
receptor resulted in the generation of larger oligomers, as anticipated. The researchers then successfully
applied the new method to a member of the G protein-coupled receptor (GPCR) family.
16. Reactivation of PTEN Tumor Suppressor for Cancer Treatment Through Inhibition of a
MYC–WWP1 Inhibitory Pathway
Highlighted by M. Helena Vasconcelos
Reactivation of the phosphatase and tensin homologue deleted on chromosome 10 (PTEN), a
tumor suppressor which is often inactivated in various human cancers, could be an effective approach
for cancer treatment [25]. A recent publication by Lee et al. [26] identified a new potential target whose
inhibition could restore normal PTEN functions: a ubiquitin E3 ligase (WWP1), which is an upstream
regulator of PTEN dimerization and membrane localization, may be transcriptionally activated by
the MYC proto-oncogene, and has previously been found overexpressed in some human cancers. In
addition, through structure simulation and biochemical analyses, this study identified indole-3-carbinol
(a natural compound found in cruciferous vegetables) as a potent pharmacological WWP1 inhibitor
which reduced tumor growth in a mouse model of prostate cancer. This work may also encourage the
discovery of new PTEN reactivators to treat cancer.
17. Derivatives of the Natural Alkaloid Matrine: New Anti-Fibrotic Tools in the Fight Against
Idiopathic Pulmonary Fibrosis
Highlighted by Sandra Gemma
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease that results in scarring and
thickening of the lungs by largely unexplained mechanisms, with consequent progressive loss of lung
function. Treatment of IPF relies on pirferidone and nintedanib, whose mode of action is not completely
understood yet. Moreover, the efficacy of these drugs is unsatisfactory, so novel leads are urgently
required. Li L. and colleagues [27] modified the structure of matrine, an alkaloid derived from a
traditional Chinese medicine with known anti-fibrotic activity, by introducing specific substituents at the
pyrrolizidine core. Most of the prepared derivatives showed improved anti-fibrotic activity compared
to the reference alkaloid, coupled to reasonable selectivity indexes, and clear-cut structure–activity
relationships were observed. Importantly, the authors dissected the biological pathway affected by
the best anti-fibrotic compound arising from their study and discovered that it could involve the
repression of TGFβ/Smad signaling by affecting the cytoplasm-to-nuclear translocation of Smad2/3.
Taken together, the data presented in this study could contribute to the discovery of novel candidate
drugs for the treatment of IPF.
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18. Multi-Targeting Therapy for Glioblastoma: A Promising New Design
Highlighted by Stefania Galdiero
Brain cancer is a major public health problem worldwide and a leading cause of death.
Glioblastoma is one of the most aggressive and common malignant brain tumors with a median survival
of less than two years. Unfortunately, the success of glioma chemotherapy is hampered by poor drug
penetration across the blood–brain barrier (BBB) and consequent low intratumoral drug concentration.
Fan et al. effectively designed a multi-targeting hybrid carrier (Pep-MLHA hybrid nanoparticles
(HNPs)) nanosystem based on a hyaluronic acid (HA)-modified polymer and a multi-targeting peptide.
HNPs showed a strong penetration ability into the core of three-dimensional tumor spheroids and
an efficient capability of crossing an in vitro BBB model. The authors also evaluated the in vivo brain
tumor-penetrating capability and targeting properties of HNPs, as well as the therapeutic efficacy of
docetaxel (DTX)-loaded HNPs. HNPs induced enhanced tumor localization, and DTX-loaded HNPs
showed negligible systemic toxicity and enhanced therapeutic efficacy, with significantly improved
survival rates of intracranial glioma-bearing rats. Such a design strategy is opening a promising avenue
to develop multi-targeting hybrid systems as new delivery tools with superior therapeutic effects for
glioma treatment [28].
19. New Potential Therapeutics for Gastrointestinal Stromal Tumors
Highlighted by Christopher Hulme
Gastrointestinal stromal tumors (GISTs) represent the most prevalent mesenchymal tumors in
the digestive tract where discovery of the c-kit mutant was a major breakthrough in GIST pathology,
affording a drugable therapeutic target. Liu et al. [29] have recently discovered a Type 2 inhibitor 1
(CHMFL-KIT-64) (Figure 2) which is potent against both wild-type c-KIT and the array c-KIT T670I
mutants. The molecule exhibits and excellent PK profile in several different species, demonstrating
promising in vivo efficacy c-KIT mutant mediated mice models in addition to c-KIT wild-type primary
cells, demonstrating imatinib resistance. As such, the overall profile of the molecule enticingly indicates
that it may be a possible clinical candidate for gastrointestinal stromal tumors.
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nanoparticles (HNPs)) nanosystem based on a hyaluronic acid (HA)-modified polymer and a 
multi-targeting peptide. HNPs showed a strong penetration ability into the core of 
three-dimensional tumor spheroids and an efficient capability of crossing an in vitro BBB model. The 
authors also evaluated the in vivo brain tumor-penetrating capability and targeting properties of 
HNPs, as well as the therapeutic efficacy of docetaxel (DTX)-loaded HNPs. HNPs induced enhanced 
tumor localization, and DTX-loaded HNPs showed negligible systemic toxicity and enhanced 
therapeutic efficacy, with significantly improved survival rates of intracranial glioma-bearing rats. 
Such a design strategy is opening a promising avenue to develop multi-targeting hybrid systems as 
new delivery tools with superior therapeutic effects for glioma treatment [28]. 
19. New Potential Therapeutics for Gastrointestinal Stromal Tumors 
Highlighted by Christopher Hulme 
Gastrointestinal stromal tumors (GISTs) represent the most prev lent mesenchymal tum rs in 
the digestive tract wher  discovery of the c-kit mutant was a major breakthrough in GIST pathol gy, 
affording a drugable therapeuti  target. Liu et l. [29] have recently discovered a Type 2 inhibitor 1 
(CHMFL-KIT-64) (Figure 2) which is potent against both wild-type c-KIT and the array c-KIT T670I 
mutants. The m l cule exhibits and excellent PK profile in several different species, emonstrating 
promising in vivo efficacy c-KIT mutant mediat d mice mod ls in addition to c-KIT wil -type 
primary cells, demonstrating imatinib resistance. As such, the overall profile of the molecule 
enticingly indicates that it may be a possible clinical candidate for gastrointestinal stromal tumors. 
 
Figure 2. Structure of CHMFL-KIT-64. .
20. Directly Targeting Riboswitches with Small Molecules to Regulate Gene Expression:
Identification of PreQ1 Riboswitches Ligands
Highlighted by Simona Collina
Riboswitches are regulatory, noncoding RNA aptamers that regulate gene expression by binding to
specific small molecules. Particularly, the PreQ1 riboswitch governs the expression of genes responsible
for the biosynthesis of queuosine (Q), a factor of key importance in bacterial virulence. Its cognate
ligand is PreQ1 (7-aminomethyl-7-deazaguanine), a modified guanine-derived nucleobase [30].
In their study, Schneekloth and co-workers discovered a new class of small molecules that bind
directly to PreQ1 riboswitches. A small-molecule microarray (SMM) screening on the aptamer domain
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of the PreQ1 riboswitch of Bacillus subtilis led to the identification of 20 hit compounds from a library
of 26,227 molecules. Compounds showing selective binding over other RNAs were fully characterized
through a series of orthogonal biophysical experiments, including NMR techniques, fluorescence
titration, and in-line probing experiments. As a result, the authors identified three molecules as
valuable starting material for developing compounds specifically tailored to target the bacteria-specific
Q biosynthetic pathway.
This work highlights challenges in developing ligands for functional RNAs and in understanding
the behavior of small synthetic compounds that bind to and modulate the function of complex RNAs.
21. Discovery of Protein–Protein Interaction Stabilizers by Site-Directed
Fragment-Based Screening
Highlighted by Michael Gütschow
In contrast to disruptors of a protein–protein interaction (PPI), low-molecular-weight stabilizers of
PPIs are relatively scarce [31]. The groups of Christian Ottmann at the Laboratory of Chemical Biology,
Eindhoven University of Technology, and Michelle R. Arkin at the Department of Pharmaceutical
Chemistry and Small Molecule Discovery Center, University of California, together with collaborators
have provided a highly interesting study on a site-directed screening technique to successfully select
fragments that enhance the affinity between protein partners [32]. Using the example of the interaction
between the hub protein 14-3-3 and the phosphorylated peptide derived from Estrogen Receptor
α (ERα), a 1600-member disulfide library was applied, capable of generating fragment conjugation
through disulfide trapping. Conjugation was analyzed by intact protein MS and exemplarily studied
in fluorescence anisotropy experiments. The authors identified stabilizers that increase the 14-3-3/ERα
affinity up to 40-fold. The molecular mechanism of cooperativity was impressively elucidated by
means of multiple X-ray co-structures.
22. The Short-Chain Fatty Acid Pentanoate as A Potent Immunomodulatory Molecule
Highlighted by George Kokotos
Short-chain fatty acids (SCFAs) such as acetate (C2), propionate (C3), and butyrate (C4), which
are generated by bacterial fermentation of dietary fiber in the intestinal lumen [33], have attracted a
lot of interest because they exert immunomodulatory effects. A recent study demonstrates that the
physiologically abundant SCFA pentanoate (C5) is a potent regulator of immunometabolism [34]. It
induces IL-10 production in lymphocytes by reprogramming their metabolic activity towards elevated
glucose oxidation. In experimental mouse models, it mediates protection from autoimmune pathologies,
shows a potent histone deacetylase-inhibitory activity in CD4+ T cells, inhibits the generation
of small-intestinal Th17 cells, and ameliorates segmented filamentous bacteria (SFB)-promoted
inflammation in the central nervous system. Thus, pentanoate might be of therapeutic relevance for
the treatment of inflammatory and autoimmune diseases.
23. Small-Molecular-Weight Synthetic Benzophenone Derivatives as New Potential Breast and
Prostate Anticancer Drugs
Highlighted by Carlo Siciliano
Brest and prostate cancers are two common invasive tumors causing death in women and men,
respectively. The preferred treatment for prostate cancer is hormone therapy, but patients can develop
resistance to long-time androgen deprivation therapy. Surgery, radiation, and/or chemotherapy
are often drastic treatment against breast cancer. Novel drugs and targeted delivery of clinically
approved anticancer drugs to tumor cells can ameliorate the outcome of these kinds of cancer, reducing
toxicity and unwanted side effects. The effectiveness and benefits of synthetic small-molecular-weight
compounds as potential anticancer drugs are currently under assessment. These compounds are
often affordable by structural tuning of natural molecular frameworks. Recently, five differently
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substituted 2-hydroxybenzophenones were synthesized by a general scheme in which the 1,4-conjugate
addition/intramolecular cycloaddition/dehydration of nitromethane was a key step in the tuning of
natural chromone scaffolds [35]. All new benzophenones were tested in vitro for their antiproliferative
activities on different breast and prostate cancer cell lines. A detailed investigation highlighted very
good cytotoxicity effects, resulting in cell detachment/death, and high specificity for all derivatives
with respect to doxorubicin used as a reference.
24. Sex-Specific Leukotriene Formation is Causative for Sex Dimorphism in Murine
Asthma-Like Features
Highlighted by Raffaele Capasso
Asthma is a common airway inflammatory disease whose incidence and severity are age- and
sex-dependent. In particular, this disease preponderates in women versus men. To date, sex has not
been considered as a discriminant factor in the pharmacological therapeutic approach of asthma.
Leukotrienes (LT) are lipid mediators with a pro-inflammatory role in asthma, and recently a sex
disparity in their production during allergen sensitization has been demonstrated [36]. Particularly,
allergen sensitization selectively increased pulmonary LT biosynthesis in female mice. These sex
differences in LT synthesis significantly affect the development of asthma-like features such as airway
hyperreactivity and lung inflammation, which are more severe in females. In addition, according to
evidence from other inflammatory conditions [37,38], different types of LT modifiers (i.e., montelukast
and zileuton) currently used in therapy, prevent asthma-like features only in female mice. These data
suggest a sex-dependent LT production as a basic mechanism of sex dimorphism in allergic asthma
and strongly prompt for potential gender-tailored asthma therapy.
25. New Asymmetric Pd-Catalyzed Synthesis of Nucleoside Analogs
Highlighted by Luigi A. Agrofoglio
Nucleoside analogs are used not only as building blocks in the genetic code but also as biosynthetic
intermediates, energy donors, metabolic regulators, and cofactors in enzymatic processes. Thanks to
the broad spectrum of their biological functions, they are identified as pharmaceutical lead anticancer,
antiviral and antibacterial compounds, for the treatment of metabolic and genetic diseases. They
are mostly synthesized by the coupling of activated bases with anomerically activated sugars using
traditional Vorbruggen glycosylation, with poor yields and diastereoselectivities with substrates
lacking a 2′ assisting group. The group of Barry M. Trost at Stanford University [39] has developed a
new catalyst system that enables the enantioselective synthesis of pyrimidine nucleoside analogs from
acyclic N-heterocyclic amide ethers, with a broad substrate scope in excellent yields (up to 96%) and
diastereo- (>20:1) and enantioselectivity (up to 99.5% ee). The new Pd catalyst system (Cp(allyl)Pd
(cat.) and (S-S)-ligand (cat.) in presence of NIS in CH2Cl2, enables the enantioselective synthesis of
pyrimidine nucleoside analogs bearing an iodide functional group handle for further functionalization,
with a broad substrate scope via iodoetherification.
It is believed that these data have a great potential to design pyrimidine nucleoside derivatives
from 5- to 12- membered rings.
26. Experimental Data Shed Light on the Molecular Basis of Cancer Resistance
Highlighted by Rino Ragno
Venetoclax (Ven ABT-199) is the first BCL-2 antagonist approved for Chronic Lymphocytic
Leukemia (CLL), and Acute Myeloid Leukemia (AML) therapy in 2016. Ven molecular mechanism
of action displays a direct of protein-protein interfering with BH3 preventing BCL-2 anti-apoptotic
effect. Birkinshaw et al. based on experimental structural data reported a detailed comparison
between ABT-199 complexed either with BCL-2 or its mutated forms, being the G101V mutation mainly
responsible for the CML acquired resistance [40]. The valine replacement induces a conformational
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change causing a rearrangement of venetoclax binding mode weakening the drug affinity by a negative
modulation with sub-pockets P2 and P4. This was further assessed by inspection of G101A mutation
which did not display any conformational rearrangement. F104L mutation structural analysis did not
show any substantial conformational changes, but just a slight alteration of the Ven’s chlorophenyl
moiety binding. Similar observations resulted also by inspection of S55746, a BCL-2 selective compound,
currently under development [41]. In conclusion the paper clearly demonstrates the role of structural
investigation to shed light on molecular mechanisms for the acquisition of cancer resistance.
27. PROTACing the UnPROTACable
Highlighted by Diego Muñoz-Torrero
PROteolysis TArgeting Chimeras (PROTACs) are hybrid compounds in which a ligand for an E3
ligase and a ligand for a target protein (protein of interest, POI) are connected through a linker. Upon
formation of a ternary complex POI–PROTAC–E3 ligase, the POI is ubiquitinated and degraded by
the proteasome. Thus, PROTACs have emerged as promising drug candidates and powerful tools for
target validation. An important question that remained unclear was whether optimal POI–E3 ligase
pairs exist or whether any potential combination could be addressed. The latter hypothesis has been
soundly addressed by the group of Ciulli, with a novel PROTAC that targets a POI–E3 ligase pair
considered unPROTACable: BRD9, an active bromodomain which is involved in MYC transcription
and proliferation of leukemic cells and the von Hippel–Lindau (VHL) E3 ligase. After the elegant
design of three generations of compounds, VZ185 (Figure 3) was identified as a potent, fast, and
selective degrader of BRD9 (half-degrading concentration 1.8 nM; maximal degradation 95%), with
very potent cytotoxicity on leukemia EOL-1 and malignant rhabdoid tumor A-204 cells. A plethora of
POI–E3 ligase combinations are awaiting the discovery of novel PROTACs [42]!
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